BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.13
8.69
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
Cash Equivalents
BioCryst Pharmaceuticals Inc
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
|
Cash Equivalents
$78.4m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
21%
|
CAGR 10-Years
-4%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Equivalents
$7.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Equivalents
$5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Equivalents
$9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Equivalents
$6.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Equivalents
$2B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
BioCryst Pharmaceuticals Inc
Glance View
BioCryst Pharmaceuticals Inc., a beacon in the realm of niche biopharmaceutical innovations, has carved its path by focusing on the development of novel oral drugs that address rare and serious medical conditions. Anchored by its expertise in small molecule therapies, BioCryst operates at the intricate intersection of biology and chemistry, designing drugs that intervene in essential biological pathways. Its flagship product, ORLADEYO® (berotralstat), received a significant nod of approval when it was launched as the first oral, once-daily prophylactic treatment for hereditary angioedema (HAE). This rare condition, characterized by recurrent swelling attacks, previously had limited treatment options, often requiring cumbersome and painful injections. The oral nature of ORLADEYO filled a critical unmet need, propelling the company to a lucrative frontier within the pharmaceutical market. Revenue generation for BioCryst is firmly rooted in the licensing and sale of its proprietary drugs. With ORLADEYO, the company has not only achieved a foothold in a specialty pharmaceutical market but also laid a foundation for sustainable financial growth. Through strategic pricing and distribution channels, supported by collaboration with global healthcare partners, BioCryst maximizes its market reach while focusing on adding to its pipeline with promising candidates in various stages of clinical development. Its approach is a careful blend of scientific innovation and business acumen, ensuring that the impacts of their breakthroughs are not only felt in prolonged patient lifespans but also reflected in the company’s bottom line.
See Also
What is BioCryst Pharmaceuticals Inc's Cash Equivalents?
Cash Equivalents
78.4m
USD
Based on the financial report for Sep 30, 2024, BioCryst Pharmaceuticals Inc's Cash Equivalents amounts to 78.4m USD.
What is BioCryst Pharmaceuticals Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
-4%
Over the last year, the Cash Equivalents growth was -48%. The average annual Cash Equivalents growth rates for BioCryst Pharmaceuticals Inc have been -27% over the past three years , 21% over the past five years , and -4% over the past ten years .
You don't have any saved screeners yet
